Anavex Dialog med EMA om godkendelse af 2-73 i Alzheimer!!!
-
Jeg tvivler meget stærkt på, at dr. Marwan Sabbagh gider blive smidt under bussen af Anavex. Mon ikke han har læst et evt peer review manuskript inden udnævnelsen og de udtalelser, der er i den.
God weekend.
-
"We are activately...acti... activily"
Ham Misling lyder sq meget sjov.
Man kunne dog ikke høre nogen hund i baggrunden
Der var vel ikke rigtig nogen nyheder idag. Det havde jeg heller ikke forventet.
Havde lidt svært ved at høre Q&A pågrund af støj.
Nogen der har en bemærkning at knytte til Q&A? -
Har læst transcript fra dagens cc.
Link på FB https://www.facebook.com/groups/1428015073895117/permalink/7805928752770352/
Ikke nogle faste tidslinier !
Men ansøgning om approval pågår med EMA i en dialog med dem.
Peer review på rette spor, men tidslinien ude af Anavex's kontrol.
FDA og dialog med dem kommer på rette tid henset problemerne med antistofferne og manglende accept af brugen hos pts. NB Aduhelm opgivet og Lecanemab sælger skidt og pts. gruppen er begrænset.
Rett ikke opgivet. De så stærk effekt i behandlingsarmen og klart bedre end trofinetide, som pt er godkendt. De har fundet problemet med placeboarmen/-effekt - for lille gruppestørrelse (30) en eller enkelte outlinerer forstyrrer billedet.
Det lyder som om Anavex håber, at flere data i rett vil kunne bringe positive indstillinger fra myndighederne. Alternativt et nyt 12 ugers forsøg med 180 pts randomiseret 1:1 med 90 pts i hhv behandling og placebo.
Synes stadig det lyder super interessant
-
Missling svarede at de endnu ikke har submit deres ansøgning til EMA og at de vil give en update så snart de ansøger.
Han kan heller ikke commit sig til en deadline for submission af ansøgningen på baggrund af et sæt data, som han selv mener er “entire”.
Er jeg den eneste som er skeptisk på de udmeldinger fra denne CC?
Jeg er total forvirret. -
I og med submission til EMA sker i dialog med EMA kan han jo ikke vide, hvad der dukker op undervejs.
Men som jeg forstår, er der flere "pakker" data de løbende arbejder på. Når de foreligger færdige efter endt dialog sker endelig submission (ansøgning). På det tidspunkt kommer en meddelelse fra Anavex.
Man får ganske enkelt ikke en fast indikation på tidspunkt på noget pr definition. Og det er ikke usædvanligt i biotech.
-
En beskrivelse af EMA ansøgningsproceduren for en markedsføringsgodkendelse af et nyt præparat findes på s. 10 i denne pjece. Herunder tidsramme og aktiviteter, der foregår i de forskellige faser af forløbet, se
-
Mayomobile med lidt opdateringer i dag:
https://www.sotcanalytics.com/Rett kan overraske positivt jf dagens cc som også bemærket af Mayomobile.
Vil ikke undre, hvis voucheren kan komme i spil
-
-
Hej TTTDK.
Ang. dit spørgsmål, hvor AVXL er i processen, så har de fremsendt en ansøgning d. 20.11.23 og modtaget svar fra EMA d. 19.2.23, at man er villig til at undersøge om, man vil kunne tildele dem en alm. genere (ikke fast speed) markedsføringsgodkendelse. (se link)
Iflg. timelinien skulle man således være ca. 3 mdr. henne i processen, der regnes at tage ca. 12 mdr.
-
Hvis nogen ikke fik hele rapporten læst, så er den her.
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2024 Earnings Call Transcript February 7, 2024
Anavex Life Sciences Corp. beats earnings expectations. Reported EPS is $-0.0001, expectations were $-0.14. AVXL isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).
Operator: Good morning. Welcome to the Anavex Life Sciences Fiscal 2024 First Quarter Conference Call. My name is Clint Tomlinson and I will be your host for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. And during this session, if you would like to ask a question, please use the Q&A box or raise your hand. Please note during this conference - this conference is being recorded. The call will be available for replay on Anavex's website at www.anavex.com. With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Sandra Boenisch, Principal Financial Officer. Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements.
These statements are only predictions based on current information and expectations and involve the number of risks and uncertainties. We encourage you to review the company's filings with the SEC. This includes without limitation the company's forms 10-K and 10-Q, which identify the specific factors that may cause actuary results or events to differ materially from those described in these forward-looking statements. These factors may include without limitation risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. And with that, I would like to turn the call over to Dr. Missling.
Christopher Missling: Thank you, Clint, and good morning, everyone. Thank you for being with us today to review our most recently reported financial results and to provide our quarterly business update. We are poised for a very exciting year for Anavex. In December, the Committee for Medicinal Products for Human Use within the European Medicines Agency agreed to the oral blarcamesine for Alzheimer disease is eligible for submission of an application for a Union Marketing Authorisation in the EU under the European Medicines Agency centralised procedure. The market authorization would allow direct market access throughout the European Union for oral blarcamesine for the treatment of Alzheimer disease. We are actively engaged on this process and aiming to submit the market authorization application as early as possible in 2024.
Full data from the blarcamesine in Alzheimer's disease Phase 2/3 randomized clinical trial is forthcoming and will be published in an upcoming peer-reviewed journal. Also, we'd like to mention that the respective open-label extension 96-week trial ATTENTION-AD is ongoing. Top line data from ANAVEX2-73-RS-003 Phase 2/3 EXCELLENCE pediatric clinical trial was announced last month. We intend to further assess the results and discuss with the regulatory authorities next steps. A high enrollment rate into the OLE open-label extension of over 91%, as well as the high level of requests for the Compassionate Use Program of 93%, provide solid numerical evidence for the positive real world evidence reported by patients and their caregivers with Rett syndrome under Compassionate Use Authorization.
Previously, we announced the first entire clinical gene pathway data from the ANAVEX2-73-RS-002 AVATAR Rett syndrome trial. We believe that this is the first time a whole genome exome analysis comparing drug and placebo in patients with Rett syndrome was performed, and we believe the results confirm that Rett syndrome is indeed a neurodevelopmental disorder with a key metabolic component, which can be addressed with therapeutic intervention and is likely relevant for other neurodevelopmental diseases as well. Related to ANAVEX3-71, our second clinical small molecule, we were pleased to announce the initiation of the U.S. FDA cleared placebo-controlled Phase 2 trial of ANAVEX3-71 for the treatment of schizophrenia, which is expected to begin in the second quarter of calendar 2024.
Regarding the Parkinson disease program, we are in preparation to initiate the ANAVEX2-73 imaging-focused trial and the ANAVEX2-73 Phase 2b/3 six months trial. For Fragile X, we believe new disease specific translatable and objective biomarker data generated recently with ANAVEX2-73 should be strengthening the support for the initiation of the potentially pivotal ANAVEX2-73 Phase 2/3 clinical trial in Fragile X. Related to a new rare disease, we are also preparation to initiate a potentially pivotal ANAVEX2-73 Phase 2/3 clinical trial. We are also expecting further peer-reviewed clinical publications involving ANAVEX2-73 and ANAVEX3-71. Last month, we announced a new peer-reviewed publication in clinical pharmacology and drug development, findings from ANAVEX3-71, first in human study, which are key achieved its safety objectives.
Spørgsmålene fra diverse er ikke med.
Mvh
-
Vores ven MayoMobile har fundet et link, der kan berolige de der synes peer review artiklen lader vente på sig.
-
"This cross-sectional analysis of clinical trials published in 2015 in 6 journals with a high impact factor found that by the time of publication, the median data age was nearly 3 years. The median publication time was more than 1.2 years, with 18.5% of trials taking 2 or more years to be published."
Potentielt lige på trapperne, ud fra medianen. 1 til 5 for at vi skal vente 12 mdr. eller mere.. det må gå som det går.
Værdien er banket så meget i kælderen, at det kun kan gå fra ringe til rigtig ringe efterhånden, hvis udfaldet ikke er som vi håber.
-
List søndagslæsning om "cortical gray matter"
Let tilgængelig:
https://news.uthscsa.edu/thinning-of-brain-region-may-signal-dementia-risk-5-10-years-before-symptoms-2/Videnskablig artikel:
https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13600MayoMobile:
https://www.sotcanalytics.com/archive-2023/brain-preservationNæppe megen tvivl om, at bevaring af hjernemassen er afgørende for at undgå demens og end og tidlig død.
Blarcamesine bevarer hjernemassen bedre en placebo med en p værdi på 0,0005. Derfor håb om, at bl.a demens kan afhjælpes og en livstidsforlængelse opnås.
Fra Anavex's meddelelse i oktober 2023:
"In addition, validated biomarkers of amyloid beta pathology, plasma Aβ42/40 ratio increased significantly (P = 0.048), demonstrating strong anti-amyloid effects of blarcamesine in Alzheimer's disease patients, while MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing treatment to placebo" https://www.anavex.com/post/anavex-sphase2b-3trialofblarcamesine-anavex-2-73-inpatientswithalzheimer-sdiseaseGlæder mig til peer review artiklen
God søndag.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind